3-(Trifluoromethyl)-1,2-oxazole-5-carboxylic Acid - CAS 251912-75-1
Catalog: |
BB056974 |
Product Name: |
3-(Trifluoromethyl)-1,2-oxazole-5-carboxylic Acid |
CAS: |
251912-75-1 |
Synonyms: |
3-(Trifluoromethyl)-5-isoxazolecarboxylic Acid; 3-(Trifluoromethyl)isoxazole-5-carboxylic Acid |
IUPAC Name: | 3-(trifluoromethyl)-1,2-oxazole-5-carboxylic acid |
Description: | 3-(Trifluoromethyl)-1,2-oxazole-5-carboxylic acid is a useful reagent for organic synthesis processes. It is used in the preparation of isoxazolyl-substituted oxazolidinones with potential antibacterial properties. |
Molecular Weight: | 181.06 |
Molecular Formula: | C5H2NO3F3 |
Canonical SMILES: | C1=C(ON=C1C(F)(F)F)C(=O)O |
InChI: | InChI=1S/C5H2F3NO3/c6-5(7,8)3-1-2(4(10)11)12-9-3/h1H,(H,10,11) |
InChI Key: | XJNNIVRCBNOKLS-UHFFFAOYSA-N |
References: | Pae, A. N., et al. Bioorg. Med. Chem. Lett., 9, 2679 (1999). |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
AU-2018360857-A1 | Modulators of the integrated stress pathway | 20171102 |
CA-3080806-A1 | Modulators of the integrated stress pathway | 20171102 |
TW-201927756-A | Integrating stress pathway regulator | 20171102 |
WO-2019090076-A1 | Modulators of the integrated stress pathway | 20171102 |
BR-112020008839-A2 | modulators of the integrated stress pathway | 20171102 |
EP-3710428-A1 | Modulators of the integrated stress pathway | 20171102 |
KR-20200096522-A | Modulators of the integrated stress pathway | 20171102 |
US-2020345727-A1 | Modulators of the integrated stress pathway | 20171102 |
CN-112204009-A | Modulators of integrated stress pathways | 20171102 |
JP-2021501786-A | Modulator of integrated stress pathway | 20171102 |
PMID | Publication Date | Title | Journal |
4973 | 19760401 | Hyperactive children and the efficacy of psychoactive drugs as a treatment intervention | The American journal of orthopsychiatry |
Complexity: | 193 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 180.99867741 |
Formal Charge: | 0 |
Heavy Atom Count: | 12 |
Hydrogen Bond Acceptor Count: | 7 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 180.99867741 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 63.3Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 1.1 |
-
Catalog: BB058457
((R)-5-Oxopyrrolidine-2-carbonyl)-L-glutamic Acid
Detail
-
Catalog: BB069213
(-)-(18-Crown-6)-2,3,11,12-tetracarboxamide
Detail
-
Catalog: BB054889
(+)-(2S,5R)-1-Allyl-2,5-dimethylpiperazine, (+)-Camphoric Acid Salt
Detail
-
Catalog: BB072386
(+)-(S)-(R)-BPPFA
Detail
-
Catalog: BB056914
(-)-(2S,3S)-Viridifloric Acid Acetonide
Detail
-
Catalog: BB069468
(+)-(S,S,S)-Ciramadol
Detail
-
Catalog: BB055796
(-)-(1S,2R)-1,2-Dihydro-1,2-naphthalenediol
Detail
-
Catalog: BB072005
(+)-(3-Bromopropyl)boronic Acid Pinanediol Ester
Detail
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS